![](/img/cover-not-exists.png)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation–Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
Spigel, David R., Reynolds, Craig, Waterhouse, David, Garon, Edward B., Chandler, Jason, Babu, Sunil, Thurmes, Paul, Spira, Alexander, Jotte, Robert, Zhu, Jin, Lin, Wen Hong, Blumenschein, GeorgeLanguage:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2018.02.022
Date:
March, 2018
File:
PDF, 287 KB
english, 2018